Johnson & Johnson is counting on its newly launched psoriasis pill to become its next cash cow. Investors want to know if it ...

Adding a dual GLP-1/GIP receptor agonist to the psoriasis drug ixekizumab (Taltz) significantly improved outcomes in adults ...

A new study has found that biologic class and treatment sequencing influences psoriatic arthritis risk in patients with ...

Patients with active psoriatic arthritis who have an inadequate response to TNF inhibitors, mainly those with elevated ...

Bristol-Myers Squibb Co. earned a federal judge’s final approval of a $239 million class settlement, resolving allegations from investors that acquired company Celgene Corp. misrepresented a multiple ...

MoonLake Immunotherapeutics has recently released its 10-Q report. The company is a clinical-stage biotechnology firm focused ...

MoonLake conducted a positive final pre-BLA (Biologics License Application) meeting with the U.S. Food and Drug Administration (FDA), where ...

The United States Food and Drug Administration recently approved Sotyktu TM (deucravacitinib) for the treatment of active psoriatic arthritis (PsA) among adults. Which of the statements below about ...

A comparative analysis identifies the top IL-23 inhibitors that were least likely to be associated with the development of ...

The European approval of Sotyktu for active psoriatic arthritis represents an important advancement in addressing both the ...

Background Patients with psoriasis (PsO) are at increased risk of developing psoriatic arthritis (PsA). Emerging evidence ...